The UK and US have hammered out a important bilateral deal that will preserve zero levies on British pharmaceutical exports going into the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has committed to boost spending on pharmaceuticals through the NHS. This commitment secures that import taxes on these crucial products will be held at nothing for a timeframe of 36 months.
This agreement follows previous statements to significantly raise duties on patented drug imports, with increases floated reaching double the cost.
"This deal between the United Kingdom reinforces the worldwide climate for cutting-edge drugs and establishes long-overdue equity to American-British pharmaceutical trade," a release noted.
Trade Significance
Medicines constitute one of the Britain's biggest exports to the US, which is easily the biggest buyer for leading British pharmaceutical firms.
Export figures show that in the year to the end of September, the UK sold pharmaceutical products totaling £11.1bn to the US. This amount made up a significant portion of all goods exports in that span.
"This guarantee protects jobs, increases capital expenditure and sets the stage for the UK to emerge as a international leader for biotech and pharma," the Business and Trade Secretary remarked.
Detailed British Pledges
The deal involves several specific pledges from the UK:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it considers new treatments to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a target to increase total public funding on medicines from 0.3% of GDP to 0.6 percent over the next decade.
- Payback Limit: The percentage manufacturers must refund to the NHS to control costs will be restricted at 15%. In the past, refunds topped twenty percent.
Recent Tensions
The pact comes amid a protracted row between the pharmaceutical industry and the British authorities over medicine costs and NHS adoption.
These tensions were heightened by assertions that American customers were charged several times more for the equivalent treatments than people in the other developed nations.
Recently, several major pharmaceutical investments in the UK have been halted or cancelled, while substantial funding commitments have been announced toward projects in the United States.
One official acknowledged that the NHS had to increase expenditure on treatments, noting that its expenditure on drugs had decreased as a percentage of its total funding over the last ten years.
